B2BINPAY
14.2.2024 09:22:28 CET | Business Wire | Press release
B2BinPay, the trusted blockchain-backed payment platform, has officially released its version 19 update to the public. This upgrade boasts many enhancements, including state-of-the-art instant swaps and expanded support for various blockchains. As always, B2BinPay remains dedicated to providing a seamless and secure platform for all cryptocurrency transactions.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240214263094/en/
B2BinPay v19 goes live with instant swaps and expanded blockchain support (Photo: Business Wire)
New Instant Swaps and Competitive VWAP-powered Rates
Swaps have become a preferred strategy for managing digital assets due to the direct exchange of cryptocurrencies between different addresses. This is a contrarian approach to conventional exchanges, which use the order books system for asset trading.
With B2BinPay, clients can easily access instant swaps without navigating through complicated order books and comparing prices across different venues. This is made possible with the Volume-Weighted Average Price (VWAP) tool, which automatically selects the best available price from multiple centralised platforms based on transaction volume.
In addition, the use of swaps by B2BinPay clients eliminates two blockchain commission costs, namely, the transaction to the centralised exchange and the transaction back to the B2BinPay wallet, which adds flexibility and cost-effectiveness in dealing with digital assets.
Instant swaps can be accessed through the dedicated Swaps Tab on the platform's front-end menu, along with separate wallets for each crypto asset.
Commission-Free Wallet Funding, Smooth Swapping Process
The latest release introduces a customised top-up process for swap wallets tailored to different user categories. Those with digital wallets can now take advantage of swift transactions for instant fund transfers, while owners of blockchain wallets benefit from on-chain transactions that offer both transparency and security through recorded data on the blockchain. It is crucial to note that topping up must be done in the wallet's designated currency.
In addition, users can enjoy a commission-free top-up process from their B2BinPay accounts. Note that blockchain wallets will still incur a minimal fee for on-chain transactions.
New Blockchain Network Integration: Avalanche and Polygon
B2BinPay's latest release has integrated support for two in-demand blockchains, Polygon and Avalanche. This integration brings an array of stablecoin transaction options to the platform, including popular choices like USDT, USDC, DAI, FRAX, TUSD, and EUROC on new networks.
Known for its scalability and minimal transaction fees, Polygon is a popular choice for a large number of crypto users. In comparison, Avalanche shines with its high throughput and rapid processing times, providing a powerful platform for speedy transfers.
Final Remarks
B2BinPay continues to push the boundaries of crypto processing with their latest version 19 release. This update offers clients even more flexibility, allowing them to access more blockchains and cryptocurrencies and make instant exchanges with swap wallets.
The team isn't stopping there – they are actively working on reducing fees to make their services even more cost-effective for all clients in future releases. This dedication to continuous improvement demonstrates B2BinPay's commitment to meeting the evolving needs of businesses and startups alike.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240214263094/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Doubtless Pet Care Launches to Provide Peace of Mind to Pet Parents and Help Their Pets Live Happier, Healthier Lives29.6.2026 10:15:00 CEST | Press release
Doubtless combines industry-leading pet insurance with innovative care solutions, protecting more than 6 million pets across 10 global markets Doubtless launches today with the goal of helping more pet parents across the world access quality care for the pets they love. The company brings together a leading global portfolio of pet insurance brands with a growing range of connected solutions designed to support pet parents at every stage of their pet’s life. With over 4,000 employees, Doubtless insures 6 million pets across 10 markets in North America, Europe and the United Kingdom. “Uncertainty about the financial commitments associated with having a pet should never keep families from experiencing the joy of a life with pets,” said Dirk Beeckman, CEO of Doubtless. “By harnessing the power of our international footprint, we are building on our leadership in pet insurance to create a global suite of solutions for pet parents, veterinarians and industry partners that makes pet care easie
Samsung Bioepis Announces Positive Preliminary Phase 1 and Phase 3 Data for SB27, a Proposed Biosimilar to Keytruda (Pembrolizumab)29.6.2026 09:19:00 CEST | Press release
Phase 1 study demonstrated pharmacokinetic (PK) equivalence between SB27 and Keytruda; Phase 3 study demonstrated equivalent objective response rate (ORR) at Week 24Phase 1 and Phase 3 studies expected to be completed within 2026 Samsung Bioepis Co., Ltd. announced today that the Phase 1 and Phase 3 studies on SB27, a proposed biosimilar to Keytruda1 (pembrolizumab), have met their primary endpoints. “We are excited to announce preliminary results from the Phase 1 and Phase 3 studies for SB27, our pembrolizumab biosimilar candidate. These topline positive results reinforce our scientific expertise and leadership in biosimilar development,” said Donghoon Shin, Executive Vice President and Head of Clinical Sciences Division at Samsung Bioepis. “We are on track to complete both Phase 1 and Phase 3 studies within this year. Leveraging our robust quality management system, we remain committed to advancing our biosimilar portfolio to broaden access to life-saving biologic medicines for patie
IQM Named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment29.6.2026 09:00:00 CEST | Press release
IQM today announced it has been named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260629748732/en/ IQM named a major player in the IDC MarketScape IQM believes this recognition comes as institutions worldwide move quantum computing out of shared cloud access and into infrastructure they own and operate themselves. IQM calls this Production Quantum: full-stack, open-architecture superconducting systems deployed on premises, inside customers' own data centers and HPC environments, where organizations own the hardware, build internal expertise, and run quantum processors alongside their existing classical infrastructure. According to the IDC MarketScape, "For institutions building long-term quantum programs, this means the workflows and intellectual property developed on IQM hardware remain portable." The report further advises: "Consi
Zambon Announces Positive CHMP Opinion for Hopledo® (IPX203) for Adults with Parkinson’s Disease and Moderate to Severe Motor Fluctuations29.6.2026 09:00:00 CEST | Press release
Positive CHMP opinion is based on data from the Phase 3 RISE-PD trial, which demonstrated significantly more “Good ON” time with fewer daily doses compared with immediate-release levodopa/carbidopa More than one million people are living with Parkinson’s disease in the European Union, and over 80% experience motor fluctuations during the course of their disease, highlighting the need for additional treatment options Hopledo® contains a unique formulation combining immediate-release granules and extended-release pellets, providing both a rapid onset of action and a longer duration of effect, sustaining the levodopa therapeutic effect for a longer period of time If approved, Zambon expects to make Hopledo® progressively available to patients with Parkinson’s disease across Europe starting October 2026 Zambon today announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a marketing authorization by the European M
Enhertu® Approved in the EU as First Tumor Agnostic HER2 Directed Therapy and Antibody Drug Conjugate for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors29.6.2026 08:30:00 CEST | Press release
Approval based on three phase 2 trials of Daiichi Sankyo and AstraZeneca’s Enhertu that demonstrated clinically meaningful responses across a broad range of tumors Enhertu now approved for six indications in the EU Enhertu® (trastuzumab deruxtecan) has been approved in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinion of the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from subgroups of patients with HER2 positive (IHC 3+) tumors across thr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom